LONDON: Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted cancer treatments and powerful diagnostics, announced that Shaun Chilton has been appointed Non-Executive Chairman replacing Eliot Forster, who is also stepping down from the Board. The changes will occur with immediate effect. Shaun Chilton has served as a Non-Executive Director at Avacta…
All posts tagged Avacta Group
Avacta Group acquires Coris Bioconcept to expand diagnostics business
LONDON, UK: Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announced today that it has acquired Coris Bioconcept SRL (“Coris”) for an upfront cash consideration of £7.4 million (on a debt-free/cash-free basis and subject to customary working capital adjustments), with an earnout based on future business…
AffiDX lateral flow test detects Delta Variant
LONDON, UK: Avacta Group plc announced that a study has shown that the AffiDX antigen lateral flow test detects the Delta variant of the SARS-CoV-2 virus in clinical samples and, in this small study, outperformed two lateral flow antigen tests that are commercially available in Europe. Lateral flow antigen tests are intended to provide a…
Avacta Group enters into distribution agreement with ABCAM
LONDON: Avacta Group has entered into a global distribution agreement with ABCAM plcto sell the Group’s recently developed SARS-CoV-2 research ELISA Affimer reagents. Avacta has developed Affimer reagents which can be used in a high performance ELISA laboratory test to detect the SARS-CoV-2 spike protein with high sensitivity and excellent specificity for the spike protein…
Avacta Group signs commercial partnership with Mologic
LONDON: Avacta Group has entered into a commercial partnership with Mologic Ltd to accelerate to market Avacta’s AffiDX SARS-CoV-2 lateral flow rapid antigen test. Avacta will also support antigen testing in low and middle income countries by providing access to Avacta’s spike antigen test through Mologic. The partnership will provide a faster route to market…
Avacta signs collaboration agreement with Bruker
LONDON: Avacta Group plc has entered into a collaboration agreement with Bruker Corporation to evaluate the Affimer-based, bead assisted mass spectrometry (BAMSTM) SARS-CoV-2 assay, that the Group has developed with Adeptrix Inc.. Bruker is one of the world’s leading analytical instrumentation companies providing high-performance scientific instruments and high-value analytical and diagnostic solutions to scientists globally.…
Avacta and Daewoong collaborate to develop next generation cell and gene therapies
LONDON: Avacta Group plc has agreed to establish a joint venture in South Korea with Daewoong Pharmaceutical Co. Ltd., a leading Korean pharmaceutical company, and to enter into a collaboration and license agreement for the joint venture to develop the next generation of cell and gene therapies. Avacta is the developer of Affimer® biotherapeutics and…
Avacta signs collaboration and option agreement with ADC Therapeutics
LONDON: Avacta Group plc, a biotechnology company developing novel cancer immunotherapies based on its proprietary Affimer platform, has entered a collaboration and option agreement with ADC Therapeutics SA (Lausanne, CH), a clinical-stage oncology-focused biotechnology company pioneering the development of highly potent and targeted antibody-drug conjugates for patients suffering from haematological malignancies and solid tumors. The…